Treat to target and prevention of subclinical atherosclerosis in psoriatic arthritis—which target should we choose?. (22nd February 2020)

• Record Type: Journal Article
• Authors: Cheng, Isaac T; Li, Edmund K; Wong, Priscilla C; Law, Mei Yan; Yim, Isaac C; Lai, Billy T; Ying, Shirley K; Kwok, Kitty Y; Li, Martin; Li, Tena K; Lee, Jack J; Szeto, Cheuk-Chun; Yan, Bryan P; Lee, Alex P; Tam, Lai-Shan
• Is Part Of: Rheumatology. Volume 59:Number 10(2020)
• Page Start: 2881
• Page End: 2892
• Publication Date: 2020-02-22
• Subjects: psoriatic arthritis -- carotid atherosclerosis -- arterial stiffness -- minimal disease activity -- remission target; Rheumatism -- Periodicals; Rheumatology -- Periodicals; 616.723005
• DOI: 10.1093/rheumatology/keaa025
• Languages: English
• ISSNs: 1462-0324

Abstract

Abstract: Objective: PsA patients who achieved sustained minimal disease activity (sMDA) had less subclinical atherosclerosis progression. The vascular effects of achieving other potential treatment targets, including the PsA Disease Activity Score (PASDAS) and the Disease Activity in PsA (DAPSA) score, remained uncertain. This study aimed to compare the vascular effects of achieving different treatment targets in PsA patients. Method: This is a post hoc analysis of a 2 year treat-to-target study aimed at MDA. A total of 101 consecutive PsA patients without overt cardiovascular disease were recruited. High-resolution carotid ultrasound and arterial stiffness markers were assessed annually. Low disease activity (LDA) was defined as MDA, DAPSA ≤14 or PASDAS ≤3.2. Sustained disease control was defined as achieving these targets at each visit from month 12 until month 24. Results: Ninety patients [52 male (57.8%), age 50 years (s .d . 11)] who completed 24 months of follow-up were included in this analysis. A total of 44%, 48% and 45% of patients achieved sustained DAPSA LDA (sDAPDA-LDA), sustained PASDAS LDA (sPASDAS-LDA) and sMDA, respectively. Patients who achieved sMDA had significantly less progression of carotid intima-media thickness than those who did not ( P = 0.031). Using multivariate analysis, achieving sMDA and sPASDAS-LDA had a protective effect on plaque progression, less increase in total plaque area, reduced mean intima-media thickness and reduced augmentation index after adjusting for covariates. In contrast, no significant differences in the progression of vascular parameters were demonstrated between patients who did or did not achieve sDAPSA-LDA. Conclusion: Achieving sMDA/sDASPAS-LDA, but not sDAPSA-LDA, was associated with a protective effect in subclinical atherosclerosis and arterial stiffness progression. A multidimensional domain of disease control might be better in minimizing cardiovascular risk in PsA.